From: Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
Characteristic | N° patients | % |
---|---|---|
Total number of patients | 273 | |
Age (years) | ||
Mean | 55.5 | |
SD | 13.7 | |
Menopausal status | ||
Premenopausal | 111 | 41 |
Postmenopausal | 162 | 56 |
Tumor size | ||
T1 | 58 | 21 |
T2 | 148 | 54 |
T3 | 45 | 17 |
T4 | 22 | 8 |
Lymph node status | ||
N0 | 118 | 43 |
N1 | 83 | 30 |
N2 | 72 | 27 |
Distant metastasis | ||
M0 | 256 | 94 |
M1 | 17 | 6 |
Metastatic sites location | ||
Bone | 7 | |
Liver | 3 | |
Skin | 2 | |
Brain | 2 | |
Not documented | 3 | |
Clinical stage | ||
I | 39 | 14 |
II | 137 | 50 |
III | 81 | 30 |
IV | 16 | 6 |
Tumor grade | ||
1 | 45 | 17 |
2 | 134 | 50 |
3 | 86 | 33 |
Not documented | 8 | |
Hormone receptor status, crossed results | ||
ER+PR+a | 140 | 52 |
ER+PR- | 50 | 18 |
ER-PR+ | 4 | 2 |
ER-PR- | 75 | 28 |
Not documented | 4 |